Regn7257    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
60Aplastic anemia3

60. Aplastic anemia    [ 218 clinical trials,   362 drugs,   (DrugBank: 81 drugs),   39 drug target genes,   155 drug target pathways]
Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 218 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002031-29-FR
(EUCTR)
21/12/202010/07/2020REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapyA PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY SEVERE APLASTIC ANEMIA
MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: REGN7257
INN or Proposed INN: Not Applicable
Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY
Regeneron Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 1;Phase 2United States;France;United Kingdom;Korea, Republic of
2NCT04409080
(ClinicalTrials.gov)
November 30, 202026/5/2020REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapyA Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapySevere Aplastic Anemia (SAA)Drug: REGN7257Regeneron PharmaceuticalsNULLNot yet recruiting18 YearsN/AAll48Phase 1;Phase 2NULL
3EUCTR2020-002031-29-GB
(EUCTR)
05/11/202030/06/2020REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapyA PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY SEVERE APLASTIC ANEMIA
MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: REGN7257
INN or Proposed INN: Not Applicable
Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY
Regeneron Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 1;Phase 2United States;France;United Kingdom;Korea, Republic of